Pulmozyme improves pulmonary function in cystic fibrosis (CF) patients by hydrolyzing extracellular DNA in sputum, reducing viscosity and enhancing airway clearance. 

Pulmonary Function Enhancement and Infection Risk Reduction

In patients with baseline FVC ≥40%, daily use lowers respiratory infection risk requiring parenteral antibiotics by 27–29% and boosts FEV₁ by ~5–9%. Subgroup analyses suggest twice-daily dosing may benefit older patients (>21 years) or those with FVC >85%. In severe disease (FVC <40%), FEV₁ improves significantly (9.4% vs. placebo), though infection risk reduction is nonsignificant. Efficacy persists during acute exacerbations, but cyclical dosing (e.g., 14-day intervals) is unsupported. Exercise tolerance outcomes are not specified in the description.